$EIDX News
Last published 5y ago
- 5y agoBBIOBMEAEIDXIOVABIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial OfficerGlobeNewswireREDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetica
- 5y agoBBIOEIDXStockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.GlobeNewswirePALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that...
- 5y agoBBIOEIDXBridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for MergerGlobeNewswirePALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that...
- 6y agoBBIOEIDXBridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business UpdateGlobeNewswire-Merger agreement executed between BridgeBio and Eidos Therapeutics; Potential to bring BridgeBio’s clinical and commercial development infrastructure to bear upon Eidos’ Acoramidis -New Drug...
- 6y agoEIDXEidos Therapeutics Reports Third Quarter 2020 Financial Results and Business UpdateGlobeNewswireSAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and provided an...
- 6y agoEIDXEIDX INVESTIGATION – Shareholder Rights Firm Labaton Sucharow is Investigating Eidos Therapeutics (NASDAQ: EIDX) for Potential Securities Violations and Breach of Fiduciary DutyBusiness WireNEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against clinical-stage biotech company Eidos Therapeutics. (NASDAQ: EIDX).
- 6y agoEIDXEIDX INVESTIGATION – Shareholder Rights Firm Labaton Sucharow is Investigating Eidos Therapeutics (NASDAQ: EIDX) for Potential Securities Violations and Breach of Fiduciary DutyBusiness WireNEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against clinical-stage biotech company Eidos Therapeutics. (NASDAQ: EIDX).
- 6y agoREGNCRWDAMCDKNG+5Stocks making the biggest moves midday: Regeneron, CrowdStrike, AMC Entertainment and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 6y agoMYOKBMYEIDXBBIO+11Stocks making the biggest moves in the premarket: MyoKardia, Eidos Therapeutics, DraftKings & moreCNBCThe stocks making the biggest moves in premarket trading include MyoKardia, Eidos Therapeutics, DraftKings, and more.
- 6y agoBBIOEIDXBridgeBio Pharma and Eidos Therapeutics Announce Merger AgreementGlobeNewswireBridgeBio to Acquire All Outstanding Shares of Eidos it Does Not Already Own Agreement Brings BridgeBio’s Clinical Development and Commercial Development Infrastructure to Bear Upon Eidos’...
- 6y agoEIDXEidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of DirectorsGlobeNewswireSAN FRANCISCO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in...
- 6y agoEIDXEidos Therapeutics Reports Second Quarter 2020 Financial Results and Business UpdateGlobeNewswireSAN FRANCISCO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the second quarter ended June 30, 2020 and provided an...
- 6y agoEIDXEidos Therapeutics Reports First Quarter 2020 Financial Results and Business UpdateGlobeNewswireSAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the first quarter ended March 31, 2020 and provided an...
- 6y agoEIDXEidos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Business UpdateGlobeNewswireSAN FRANCISCO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2019 and...
- 6y agoBBIOEIDXBridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor ConferencesGlobeNewswirePALO ALTO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), together with affiliate company Eidos Therapeutics (Nasdaq: EIDX) announced today that they are presenting...
- 6y agoEIDXBBIOCORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease MeasuresGlobeNewswireAG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular...
- 6y agoEIDXBBIOBridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease MeasuresGlobeNewswireAG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular...
- 7y agoEIDXBBIOEidos Therapeutics Reports Third Quarter 2019 Financial Results and Business UpdateGlobeNewswireSAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO), today reported its financial...
- 7y agoBBIOEIDXBridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos TherapeuticsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that it was unable to come to an agreement with the Special Committee formed by its subsidiary Eidos Therapeutics (NASDAQ: EIDX), a clinical-stage biopharmaceutical company developing AG10 for the treatment of transthyretin amyloidosis ( ...
- 7y agoEIDXEidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral PresentationGlobeNewswireSAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need...
- 7y agoEIDXEidos Therapeutics Special Committee Rejects Proposal from BridgeBio Pharma to Acquire SharesBusiness WireSAN FRANCISCO--(BUSINESS WIRE)--Eidos Therapeutics, Inc. (Nasdaq:EIDX) (“Eidos”) announced today that the Special Committee of its Board of Directors (the “Special Committee”) unanimously rejected the non-binding proposal dated August 8, 2019 (the “Proposal”) from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder (“BridgeBio”), to purchase all of the outstanding commo ...
- 7y agoEIDXEidos Therapeutics Confirms Receipt of Non-Binding Proposal from BridgeBio Pharma to Acquire SharesBusiness WireSAN FRANCISCO--(BUSINESS WIRE)--Eidos Therapeutics, Inc. (Nasdaq:EIDX) (the “Company”) today confirmed that it has received a non-binding proposal dated August 8, 2019 (the “Proposal”) from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder (“BridgeBio”), to purchase all of the outstanding common stock of the Company not already owned by BridgeBio. BridgeBio currently ...
- 7y agoHTGCDOCUTCDAEIDX+5Hercules Capital Completes Outstanding Fourth Quarter Originations Activity and Achieves All-Time Record of More Than $1.21 Billion in Total New Debt and Equity Commitments in 2018(1)Business WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading and largest focused specialty finance company to innovative venture growth, pre-IPO and M&A stage companies backed by leading venture capital and select private equity firms, today announced its many select investment and operating highlights for 2018.
- 8y agoHTGCWFCDOCUTCDA+4Hercules Capital Announces Second Quarter 2018 Financial Results and Quarterly Distribution of $0.31 per ShareBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, today announced its financial results for the second quarter ended June 30, 2018.
- 8y agoHTGCDOCUTCDAEIDX+7Hercules Capital Proudly Announces Eight Portfolio Companies Have Completed or Announced an IPO or M&A Liquidity Event Year-to-Date 2018Business WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, is pleased to announce the latest liquidity events for eight (8) of its portfolio companies: DocuSign, Inc., Tricida, Inc. and BridgeBio Inc./Eidos Therapeutics, Inc., wh ...